Konakion

Phytomenadione, the active ingredient in Konakion, is a Vitamin K presented as a sterile solution for intravenous and oral use. It treats vitamin K deficiency, helps prevent hemorrhagic disease of the newborn, and reverses excessive anticoagulation caused by vitamin K antagonists.

GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Konakion is a vitamin K agent used to correct deficiencies and counteract anticoagulant effects.

- Vitamin K deficiency: restores functional clotting factors to prevent bleeding. - Hemorrhagic disease of the newborn: provides prophylactic vitamin K to newborns at risk of bleeding. - Anticoagulant reversal: rapidly normalizes coagulation in patients over‑anticoagulated by vitamin K antagonists.

Adverse reactions may occur with phytomenadione administration.

Common Side Effects: - Injection site pain or erythema - Flushing or warmth sensation - Headache - Nausea or vomiting - Diarrhoea - Transient rise in liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Acute hemolysis - Severe hypotension - Thrombosis in patients with underlying clotting disorders - Persistent elevation of INR despite treatment

Use phytomenadione with clinical monitoring and appropriate patient assessment.

- Assess coagulation status: check baseline INR or PT before administration. - Monitor INR/PT after dosing: ensure therapeutic correction without overshoot. - Caution in liver disease: impaired synthesis of clotting factors may affect response. - Avoid in known hypersensitivity to vitamin K or formulation excipients. - Adjust dose in neonates: follow neonatal dosing guidelines. - Store at ambient temperature: keep in original container, protect from moisture and light.

Phytomenadione may interact with several medications affecting coagulation or vitamin K metabolism.

Major Interactions (Avoid): - Warfarin or other vitamin K antagonists: concurrent use may blunt anticoagulant effect. - Broad‑spectrum antibiotics (e.g., cephalosporins): can reduce gut flora‑derived vitamin K, altering response. - High‑dose vitamin K supplements: may cause excessive clotting.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may enhance clotting risk, monitor for thrombosis. - Cholesterol‑lowering agents (e.g., statins): potential minor effect on vitamin K pathways. - Antifungal agents (e.g., fluconazole): may alter vitamin K metabolism, require INR monitoring.